In vitro antimicrobial spectrum, occurrence of synergy, and recommendations for dilution susceptibility testing concentrations of the cefoperazone-sulbactam combination
- 1 September 1987
- journal article
- research article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 25 (9) , 1725-1729
- https://doi.org/10.1128/jcm.25.9.1725-1729.1987
Abstract
Broth microdilution tests and an antimicrobial interaction (synergy) studies using various combinations of cefoperazone and sulbactam were performed in an effort to determine the most appropriate in vitro dilution test system. The test results with cefoperazone and sulbactam were categorized as synergistic (complete or partial) for nearly 80% of the strains isolated from clinical trial patients. The results indicate that the cefoperazone-sulbactam fixed ratio (2:1) maximized the cefoperazone spectrum of activity and best approximated the parenteral formulation of the drug. The cefoperazone-sulbactam combination had a greater antimicrobial activity than did the other comparison beta-lactams, except for imipenem, tested against strains of the family Enterobacteriaceae. To be consistent with the National Committee for Clinical Laboratory Standards interpretive breakpoints for cefoperazone alone, the following MIC breakpoints should be applied to the combination (2:1 ratio): less than or equal to 16/8 micrograms/ml, susceptible; 32/16 micrograms/ml, moderately susceptible; and greater than or equal to 64/32 micrograms/ml, resistant.This publication has 14 references indexed in Scilit:
- Beta-lactamase stability of cefpirome (HR 810), a new cephalosporin with a broad antimicrobial spectrumAntimicrobial Agents and Chemotherapy, 1986
- In-vitro susceptibility of the Bacteroides fragilis group to cefoperazone, ampicillin, ticarcillin and amoxycillin combined with β-lactamase inhibitorsJournal of Antimicrobial Chemotherapy, 1986
- In vitro antimicrobial activity of cefoperazone-sulbactam combinations against 554 clinical isolates including a review and β-lactamase studiesDiagnostic Microbiology and Infectious Disease, 1985
- Comparative activities of the beta-lactamase inhibitors YTR 830, sodium clavulanate, and sulbactam combined with amoxicillin or ampicillinAntimicrobial Agents and Chemotherapy, 1984
- Antimicrobial activity of amikacin combinations against Enterobacteriaceae moderately susceptible to third-generation cephalosporinsAntimicrobial Agents and Chemotherapy, 1982
- Activity of cefoperazone and two beta-lactamase inhibitors, sulbactam and clavulanic acid, against Bacteroides spp. correlated with beta-lactamase productionAntimicrobial Agents and Chemotherapy, 1982
- CefoperazoneDrugs, 1981
- Synergistic activity of cefoperazone in combination with β-lactamase inhibitorsJournal of Antimicrobial Chemotherapy, 1981
- Principal beta-lactamases responsible for resistance to beta-lactam antibiotics in urinary tract infectionsAntimicrobial Agents and Chemotherapy, 1980
- CP-45,899, a Beta-Lactamase Inhibitor That Extends the Antibacterial Spectrum of Beta-Lactams: Initial Bacteriological CharacterizationAntimicrobial Agents and Chemotherapy, 1978